{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-005107","form_type":"8-K","ticker":"ANIK","cik":"0000898437","company_name":"Anika Therapeutics, Inc.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.965823+00:00","generated_at":"2026-06-12T03:28:21.040701+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Anika Q2 revenue rises 12% to $44.3M; raises FY2023 guidance floor to $159.5M","bullets":["Q2 revenue $44.3M (+12% YoY); net loss ($0.19)/share; adjusted EPS $0.06 vs ($0.12) prior year.","OA Pain Mgmt rev +22% to $29.3M; Joint Preservation & Restoration +5% to $12.7M.","FY2023 rev guidance raised: $159.5M-$163M (was $158M-$163M), representing 2-4% growth.","Hyalofast Phase III fully enrolled; PMA submission begins 2024; Cingal ongoing FDA discussions after Type-C meeting.","RevoMotion reverse shoulder full market launch accelerated to Sept 2023; Integrity rotator cuff patch 2024 launch on track."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-005107","json":"https://secwatch.observer/filing/0001171843-23-005107.json","markdown":"https://secwatch.observer/filing/0001171843-23-005107.md","text":"https://secwatch.observer/filing/0001171843-23-005107.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/898437/000117184323005107/0001171843-23-005107-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/898437/000117184323005107/f8k_080823.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T03:28:21.040701+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e94998124bc5ec553843f0d2fa9328a3ec65e669","claim":"Anika Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: revenue $44.3 million, net income ($2.7) million, or ($0.19) per share, EPS ($0.19) per share. Guidance raised.","evidence_excerpt":"Revenue in the second quarter of 2023 was $44.3 million, up 12% compared to $39.7 million in the second quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/898437/000117184323005107/0001171843-23-005107-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Revenue","value":"$44.3 million"},{"label":"Net income","value":"($2.7) million, or ($0.19) per share"},{"label":"EPS","value":"($0.19) per share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}